Related Experiment Videos
Spotlight on paricalcitol in secondary hyperparathyroidism
Dean M Robinson1, Lesley J Scott
1Adis International Inc., Yardley, Pennsylvania 19067, USA. demail@adis.com
Treatments in Endocrinology
|May 19, 2005
Summary
Paricalcitol effectively lowers parathyroid hormone (PTH) in patients with chronic kidney disease. This vitamin D2 analog is a safe and effective treatment option for secondary hyperparathyroidism in adults and children.
Area of Science:
- Nephrology
- Endocrinology
- Pharmacology
Background:
- Secondary hyperparathyroidism is common in chronic renal failure.
- Parathyroid hormone (PTH) plays a key role in mineral metabolism.
- Vitamin D analogs are used to manage secondary hyperparathyroidism.
Purpose of the Study:
- To evaluate the efficacy and safety of paricalcitol for secondary hyperparathyroidism in chronic renal failure.
- To compare paricalcitol with calcitriol in managing this condition.
Main Methods:
- Intravenous administration of paricalcitol.
- Clinical trials involving adult and pediatric patients with chronic renal failure.
- Assessment of serum PTH, calcium, and phosphorus levels.
Main Results:
- Paricalcitol effectively reduced elevated serum PTH levels.
- The drug was generally well tolerated in both children and adults.
- Paricalcitol demonstrated comparable efficacy and safety to calcitriol, including similar rates of hypercalcemia and elevated calcium-phosphorus product.
Conclusions:
- Paricalcitol is a valuable therapeutic option for managing secondary hyperparathyroidism in adults and children with chronic renal failure.
- It offers comparable efficacy and tolerability to calcitriol.